hotspot -WSS

hotspot

author：knowledge 2025-09-28 00:50:53 - browse：35134

Are there still too many biotech companies? How do you know when you’re in a bubble? And is there a wrong way to pronounce “TIGIT”?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Josh Schimmer and Eric Schmidt, two longtime analysts teaming up at Cantor Fitzgerald, join us for a back-to-school conversation as biotech enters the busy back third of 2023. We also discuss the latest news in the life sciences, including some scientific evolution at Biogen, new leadership at Illumina, and the future of CRISPR medicine.

For more on what we cover, here’s the news from Biogen; here’s more on Illumina; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： A single Democrat is willing to weaken Medicare negotiation power

WSS

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Readers respond to H5N1 and livestock movements, and more

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Adopting new red light myopia treatments may be short

Adopting new red light myopia treatments may be short

Case highlights the risks of experimental stem cell therapy

focus

hotspot

knowledge

Tori Bowie and the unacceptable rates of Black maternal death

Global cancer cases to surge 77% by 2050, WHO report says

In Memoriam: Notable people who died in 2023

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Medicare details structure of new drug price negotiation program

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Alkermes shareholders re

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Duchenne breakthrough therapy leaves behind pioneering families

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

focus

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Unique patient identifier: Experts argue the benefits, pitfalls

NVIDIA and Google execs on the future of AI and drug discovery

Bernie brings in new pharma CEOs to talk drug prices

focus

focus

focus

Wikipedia